Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Ligand (LGND) Breakout! -- Ignore unavailable to you. Want to Upgrade?

To: Flagrante Delictu who wrote (21354)	5/23/1998 11:54:00 PM
From: WTDEC	Read Replies (2) \| Respond to of 32384

Hello Bernie. I'm trying to catch up...started the day behind 800 LGND posts, but now only down 350. Amazing what a bottle of '89 Silver Oak helps me do !! Jumped ahead here to say I think the LLY filing is a very positive development for LGND. Now we have plenty of time to evaluate the situation. Even if approved, LGND may not see the CTCL market for the SRGN drug as being big enough to justify buying LLY's rights to it versus the cash infusion (which may be more important to LGND than future drug sales at the time the decision is made) from the sale of stock to LLY. IMO, LGND is saving LLY's tail (assuming approval) here no matter which way they go as drug is now in strong, friendly hands. Hope the Brits and your tour guide treated you appropriately. Will catch up tomorrow... Regards, Walter